deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT01932242

Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Repeat Administration of Intravenous ETI-204 in Adult Volunteers

Sponsor: Elusys Therapeutics

Conditions Inhalational Anthrax
Interventions ETI-204 Placebo
Updated 10 times since 2017 Last updated: May 2, 2019 Started: Jul 23, 2013 Primary completion: Apr 19, 2014 Completion: Apr 19, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01932242, this PHASE1 trial focuses on Inhalational Anthrax and remains completed. Sponsored by Elusys Therapeutics, it has been updated 10 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~May 2019 · 11 months · monthly snapshotCompleted~May 2019 – ~Jun 2019 · 31 days · monthly snapshotCompleted~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE1

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE1

  5. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE1

▶ Show 5 earlier versions

  1. Jun 2019 — Jan 2021 [monthly]

    Completed PHASE1

  2. May 2019 — Jun 2019 [monthly]

    Completed PHASE1

  3. Jun 2018 — May 2019 [monthly]

    Completed PHASE1

  4. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Elusys Therapeutics
Data source: Elusys Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations